Home LiteratureArticle Details
PMID: 11816795 Published · ppublish English Journal Article Review

Lewy body pathology in Alzheimer's disease.

Journal of molecular neuroscience : MN ·Vol. 17 ·No. 2 ·2001-10-00 ·Pages 225-32

Kotzbauer PT, Trojanowsk JQ, Lee VM

Abstract

Lewy bodies, the characteristic pathological lesion of substantia nigra neurons in Parkinson's disease (PD), are frequently observed to accompany the amyloid plaque and neurofibrillary tangle pathology of Alzheimer's disease (AD). However the typical anatomic distribution of Lewy bodies in AD is distinct from PD. The most common site of occurrence is the amygdala, where Lewy bodies are observed in approximately 60% of both sporadic and familial AD. Other common sites of occurrence include the periamygdaloid and entorhinal cortex, while neocortical and brainstem areas develop Lewy bodies in a lower percentage of cases. In contrast, dementia with Lewy bodies (DLB), defined by widespread neocortical and brainstem Lewy bodies but frequently accompanied by variable levels of AD-type pathology, represents the other end of a spectrum of pathology associated with dementia. The observation of Lewy bodies in familial AD cases suggests that like neurofibrillary tangles, the formation of Lewy bodies can be induced by the pathological state caused by Abeta-amyloid overproduction. The role of Lewy body formation in the dysfunction and degeneration of neurons remains unclear. The protein alpha-synuclein appears to be an important structural component of Lewy bodies, an observation spurred by the discovery of point mutations in the alpha-synuclein gene linked to rare cases of autosomal dominant PD. Further investigation of alpha-synuclein and its relationship to pathological conditions promoting Lewy body formation in AD, PD, and DLB may yield further insight into pathogenesis of these diseases.

MeSH Terms
Alzheimer Disease/genetics,pathology Amyloid beta-Peptides/metabolism Animals Brain/pathology Humans Lewy Bodies/pathology Nerve Tissue Proteins/genetics,metabolism Neurons/pathology Oxidative Stress/physiology Point Mutation/physiology Synucleins alpha-Synuclein tau Proteins/metabolism
Chemicals
Amyloid beta-Peptides Nerve Tissue Proteins SNCA protein, human Synucleins alpha-Synuclein tau Proteins
Authors & Affiliations
3 authors, click to expand affiliations / ORCID
Kotzbauer P T
Center for Neurodegenerative Disease Research, University of Pennsylvania School of Medicine, Philadelphia, USA.
Trojanowsk J Q
Lee V M
References (80)
80 references, click to expand
  1. Widespread occurrence of alpha-synuclein/NACP-immunoreactive neuronal inclusions in juvenile and adult-onset Hallervorden-Spatz disease with Lewy bodies.
    Neuropathol Appl Neurobiol. 1999 Oct;25(5):363-8 PMID: 10564525
  2. alpha-Synuclein shares physical and functional homology with 14-3-3 proteins.
    J Neurosci. 1999 Jul 15;19(14):5782-91 PMID: 10407019
  3. Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease.
    Proc Natl Acad Sci U S A. 1993 Dec 1;90(23):11282-6 PMID: 8248242
  4. Clinical and neuropathological correlates of dementia with Lewy bodies.
    Ann N Y Acad Sci. 2000;920:9-15 PMID: 11193181
  5. Enhanced vulnerability to oxidative stress by alpha-synuclein mutations and C-terminal truncation.
    Neuroscience. 2000;97(2):279-84 PMID: 10799759
  6. Alpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson's disease.
    Neurology. 2000 May 23;54(10):1916-21 PMID: 10822429
  7. Both familial Parkinson's disease mutations accelerate alpha-synuclein aggregation.
    J Biol Chem. 1999 Apr 2;274(14):9843-6 PMID: 10092675
  8. Membrane association and protein conformation of alpha-synuclein in intact neurons. Effect of Parkinson's disease-linked mutations.
    J Biol Chem. 2000 Mar 24;275(12):8812-6 PMID: 10722726
  9. The role of mitochondrial dysfunction and neuronal nitric oxide in animal models of neurodegenerative diseases.
    Mol Cell Biochem. 1997 Sep;174(1-2):193-7 PMID: 9309687
  10. Neuropathological diagnoses in elderly patients in Oslo: Alzheimer's disease, Lewy body disease, vascular lesions.
    Dementia. 1995 May-Jun;6(3):162-8 PMID: 7620529
  11. Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins.
    Proc Natl Acad Sci U S A. 1998 May 26;95(11):6448-53 PMID: 9600986
  12. Lewy body in neurodegeneration with brain iron accumulation type 1 is immunoreactive for alpha-synuclein.
    Neurology. 1998 Sep;51(3):887-9 PMID: 9748051
  13. The A53T alpha-synuclein mutation increases iron-dependent aggregation and toxicity.
    J Neurosci. 2000 Aug 15;20(16):6048-54 PMID: 10934254
  14. Lewy bodies contain altered alpha-synuclein in brains of many familial Alzheimer's disease patients with mutations in presenilin and amyloid precursor protein genes.
    Am J Pathol. 1998 Nov;153(5):1365-70 PMID: 9811326
  15. Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system.
    Neuron. 2000 Jan;25(1):239-52 PMID: 10707987
  16. The synucleins: a family of proteins involved in synaptic function, plasticity, neurodegeneration and disease.
    Trends Neurosci. 1998 Jun;21(6):249-54 PMID: 9641537
  17. Overexpression of human alpha-synuclein causes dopamine neuron death in rat primary culture and immortalized mesencephalon-derived cells.
    Brain Res. 2000 Jun 2;866(1-2):33-43 PMID: 10825478
  18. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease.
    Nat Genet. 1998 Feb;18(2):106-8 PMID: 9462735
  19. Alpha-synuclein accumulates in Lewy bodies in Parkinson's disease and dementia with Lewy bodies but not in Alzheimer's disease beta-amyloid plaque cores.
    Neurosci Lett. 1999 May 14;266(3):213-6 PMID: 10465711
  20. Chronic systemic pesticide exposure reproduces features of Parkinson's disease.
    Nat Neurosci. 2000 Dec;3(12):1301-6 PMID: 11100151
  21. Neural expression profile of alpha-synuclein in developing human cortex.
    Neuroreport. 1999 Sep 9;10(13):2799-803 PMID: 10511443
  22. Dementia with Lewy bodies.
    J Am Geriatr Soc. 1998 Nov;46(11):1449-58 PMID: 9809770
  23. Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies.
    Am J Pathol. 1998 Apr;152(4):879-84 PMID: 9546347
  24. Antibodies to alpha-synuclein detect Lewy bodies in many Down's syndrome brains with Alzheimer's disease.
    Ann Neurol. 1999 Mar;45(3):353-7 PMID: 10072050
  25. Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders.
    Science. 2000 Feb 18;287(5456):1265-9 PMID: 10678833
  26. The Lewy body variant of Alzheimer's disease: a clinical and pathologic entity.
    Neurology. 1990 Jan;40(1):1-8 PMID: 2153271
  27. Accumulation of alpha-synuclein in autonomic nerves in pure autonomic failure.
    Neurology. 2001 Apr 10;56(7):980-1 PMID: 11294945
  28. Plaque-only Alzheimer disease is usually the lewy body variant, and vice versa.
    J Neuropathol Exp Neurol. 1993 Nov;52(6):648-54 PMID: 8229084
  29. Synucleins are developmentally expressed, and alpha-synuclein regulates the size of the presynaptic vesicular pool in primary hippocampal neurons.
    J Neurosci. 2000 May 1;20(9):3214-20 PMID: 10777786
  30. The frequency of Lewy bodies in a consecutive autopsy series.
    Clin Neuropathol. 1998 Jul-Aug;17(4):204-9 PMID: 9707335
  31. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease.
    Science. 1997 Jun 27;276(5321):2045-7 PMID: 9197268
  32. Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease.
    Nat Med. 1998 Nov;4(11):1318-20 PMID: 9809558
  33. The synuclein family.
    Genome Res. 1998 Sep;8(9):871-80 PMID: 9750188
  34. alpha-synuclein promotes mitochondrial deficit and oxidative stress.
    Am J Pathol. 2000 Aug;157(2):401-10 PMID: 10934145
  35. Purification and characterization of Lewy bodies from the brains of patients with diffuse Lewy body disease.
    Am J Pathol. 1996 May;148(5):1517-29 PMID: 8623921
  36. Effects of the mutations Ala30 to Pro and Ala53 to Thr on the physical and morphological properties of alpha-synuclein protein implicated in Parkinson's disease.
    FEBS Lett. 1998 Nov 27;440(1-2):67-70 PMID: 9862427
  37. Regulation of phospholipase D2: selective inhibition of mammalian phospholipase D isoenzymes by alpha- and beta-synucleins.
    Biochemistry. 1998 Apr 7;37(14):4901-9 PMID: 9538008
  38. Origin and functional consequences of the complex I defect in Parkinson's disease.
    Ann Neurol. 1996 Oct;40(4):663-71 PMID: 8871587
  39. Wild-type but not Parkinson's disease-related ala-53 --> Thr mutant alpha -synuclein protects neuronal cells from apoptotic stimuli.
    J Biol Chem. 2000 Aug 4;275(31):24065-9 PMID: 10818098
  40. Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease.
    Nat Med. 1999 Dec;5(12):1403-9 PMID: 10581083
  41. Protofibrillar intermediates of amyloid beta-protein induce acute electrophysiological changes and progressive neurotoxicity in cortical neurons.
    J Neurosci. 1999 Oct 15;19(20):8876-84 PMID: 10516307
  42. Comparison of Lewy body variant of Alzheimer's disease with pure Alzheimer's disease: Consortium to Establish a Registry for Alzheimer's Disease, Part XIX.
    Neurology. 1999 Jun 10;52(9):1839-44 PMID: 10371532
  43. Quantitative neuropathological study of Alzheimer-type pathology in the hippocampus: comparison of senile dementia of Alzheimer type, senile dementia of Lewy body type, Parkinson's disease and non-demented elderly control patients.
    J Neurol Sci. 1991 Dec;106(2):142-52 PMID: 1802962
  44. Induction of neuronal death by alpha-synuclein.
    Eur J Neurosci. 2000 Aug;12(8):3073-7 PMID: 10971650
  45. Mitochondrial complex I deficiency in Parkinson's disease.
    J Neurochem. 1990 Mar;54(3):823-7 PMID: 2154550
  46. Alzheimer's disease: genes, proteins, and therapy.
    Physiol Rev. 2001 Apr;81(2):741-66 PMID: 11274343
  47. beta-Amyloid precursor protein metabolites and loss of neuronal Ca2+ homeostasis in Alzheimer's disease.
    Trends Neurosci. 1993 Oct;16(10):409-14 PMID: 7504356
  48. Inflammation and Alzheimer's disease pathogenesis.
    Neurobiol Aging. 1996 Sep-Oct;17(5):681-6 PMID: 8892340
  49. alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies.
    Proc Natl Acad Sci U S A. 1998 May 26;95(11):6469-73 PMID: 9600990
  50. Pure autonomic failure in association with human alpha-synucleinopathy.
    Neurosci Lett. 2000 Dec 22;296(2-3):171-3 PMID: 11109008
  51. Effect of the overexpression of wild-type or mutant alpha-synuclein on cell susceptibility to insult.
    J Neurochem. 2001 Feb;76(4):998-1009 PMID: 11181819
  52. Intraneuronal filamentous tau protein and alpha-synuclein deposits in neurodegenerative diseases.
    Biochem Soc Trans. 1998 Aug;26(3):463-71 PMID: 9765897
  53. Review: Alzheimer's amyloid beta-peptide-associated free radical oxidative stress and neurotoxicity.
    J Struct Biol. 2000 Jun;130(2-3):184-208 PMID: 10940225
  54. Convergence of Lewy bodies and neurofibrillary tangles in amygdala neurons of Alzheimer's disease and Lewy body disorders.
    Acta Neuropathol. 1996;91(5):475-81 PMID: 8740227
  55. Non-Abeta component of Alzheimer's disease amyloid (NAC) revisited. NAC and alpha-synuclein are not associated with Abeta amyloid.
    Am J Pathol. 1999 Oct;155(4):1173-81 PMID: 10514400
  56. Clinical-neuropathological correlations in Alzheimer's disease and related dementias.
    Arch Neurol. 1994 Sep;51(9):888-95 PMID: 8080388
  57. NACP, a protein implicated in Alzheimer's disease and learning, is natively unfolded.
    Biochemistry. 1996 Oct 29;35(43):13709-15 PMID: 8901511
  58. Glial cytoplasmic inclusions in white matter oligodendrocytes of multiple system atrophy brains contain insoluble alpha-synuclein.
    Ann Neurol. 1998 Sep;44(3):415-22 PMID: 9749615
  59. Sensitization of neuronal cells to oxidative stress with mutated human alpha-synuclein.
    J Neurochem. 2000 Dec;75(6):2546-54 PMID: 11080208
  60. Alpha-synuclein in Lewy bodies.
    Nature. 1997 Aug 28;388(6645):839-40 PMID: 9278044
  61. Mutant and wild type human alpha-synucleins assemble into elongated filaments with distinct morphologies in vitro.
    J Biol Chem. 1999 Mar 19;274(12):7619-22 PMID: 10075647
  62. A Drosophila model of Parkinson's disease.
    Nature. 2000 Mar 23;404(6776):394-8 PMID: 10746727
  63. Expression pattern of synucleins (non-Abeta component of Alzheimer's disease amyloid precursor protein/alpha-synuclein) during murine brain development.
    J Neurochem. 1998 Jul;71(1):338-44 PMID: 9648883
  64. Mechanisms of MPTP toxicity.
    Mov Disord. 1998;13 Suppl 1:35-8 PMID: 9613716
  65. Lewy bodies in Alzheimer's disease: a neuropathological review of 145 cases using alpha-synuclein immunohistochemistry.
    Brain Pathol. 2000 Jul;10(3):378-84 PMID: 10885656
  66. A 10-year study of the incidence of and factors predicting dementia in Parkinson's disease.
    Neurology. 2000 Apr 25;54(8):1596-602 PMID: 10762499
  67. Filamentous alpha-synuclein inclusions link multiple system atrophy with Parkinson's disease and dementia with Lewy bodies.
    Neurosci Lett. 1998 Jul 31;251(3):205-8 PMID: 9726379
  68. Alpha-synuclein immunoreactivity is present in axonal swellings in neuroaxonal dystrophy and acute traumatic brain injury.
    J Neuropathol Exp Neurol. 1999 Dec;58(12):1263-8 PMID: 10604751
  69. Ubiquitin carboxyl-terminal hydrolase (PGP 9.5) is selectively present in ubiquitinated inclusion bodies characteristic of human neurodegenerative diseases.
    J Pathol. 1990 Jun;161(2):153-60 PMID: 2166150
  70. The inflammatory response system of brain: implications for therapy of Alzheimer and other neurodegenerative diseases.
    Brain Res Brain Res Rev. 1995 Sep;21(2):195-218 PMID: 8866675
  71. Neuropathology of Parkinson's disease.
    J Neuropathol Exp Neurol. 1996 Mar;55(3):259-72 PMID: 8786384
  72. Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions.
    Science. 2000 Nov 3;290(5493):985-9 PMID: 11062131
  73. Delayed localization of synelfin (synuclein, NACP) to presynaptic terminals in cultured rat hippocampal neurons.
    Brain Res Dev Brain Res. 1997 Mar 17;99(1):87-94 PMID: 9088569
  74. Abnormalities of the electron transport chain in idiopathic Parkinson's disease.
    Ann Neurol. 1989 Dec;26(6):719-23 PMID: 2557792
  75. The Lewy-body variant of Alzheimer's disease. Clinical and pathological findings.
    Br J Psychiatry. 1993 Mar;162:385-92 PMID: 8453435
  76. Lewy bodies of Parkinson's disease contain neurofilament antigens.
    Science. 1983 Sep 9;221(4615):1082-4 PMID: 6308771
  77. Immunocytochemical co-localization of the proteasome in ubiquitinated structures in neurodegenerative diseases and the elderly.
    J Neuropathol Exp Neurol. 1997 Feb;56(2):125-31 PMID: 9034365
  78. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis.
    Science. 1983 Feb 25;219(4587):979-80 PMID: 6823561
  79. Predictors of progression in patients with AD and Lewy bodies.
    Neurology. 2000 May 9;54(9):1774-9 PMID: 10802783
  80. Dityrosine cross-linking promotes formation of stable alpha -synuclein polymers. Implication of nitrative and oxidative stress in the pathogenesis of neurodegenerative synucleinopathies.
    J Biol Chem. 2000 Jun 16;275(24):18344-9 PMID: 10747881
Article Info
Journal
Journal of molecular neuroscience : MN
Abbr.
J Mol Neurosci
ISSN
0895-8696
Published
2001-10-00
Pages
225-32
Language
English
Region
United States
NLM ID
9002991
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com